SNGX - Soligenix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0900
-0.0100 (-0.91%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1000
Open1.1000
Bid1.0500 x 2200
Ask1.0700 x 900
Day's Range1.0500 - 1.1000
52 Week Range0.6500 - 2.2000
Volume19,242
Avg. Volume153,752
Market Cap21.347M
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Moleculin Completes Enrollment in Early-Stage Cancer Study
    Zacks

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

  • Zacks Small Cap Research

    SNGX: What to Expect from the Upcoming Interim Analysis of SGX942

    Soligenix, Inc. (SNGX) is a biopharmaceutical company currently conducting two pivotal Phase 3 clinical trials with its lead development compounds. • SGX301 is in a Phase 3 trial for the treatment of cutaneous T cell lymphoma (CTCL). • SGX942 is in a Phase 3 clinical trial for the treatment of oral mucositis in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research

    SNGX: Multiple Important Catalysts on the Horizon…

    Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. In April 2019, Soligenix announced that the Phase 3 trial of SGX942 had reached the enrollment target to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • Zacks Small Cap Research

    SNGX: Interim Analysis for SGX942 Phase 3 Trial Expected in Sep. 2019…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research

    SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • Zacks Small Cap Research

    SNGX: Interim Analysis of SGX942 in Oral Mucositis in Third Quarter of 2019…

    Soligenix, Inc. (SNGX) is currently conducting the randomized, multinational, double blind, placebo controlled Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial, which is evaluating SGX942 (dusquetide) for the treatment of severe oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy. Important secondary endpoints that are being evaluated include tumor progression and overall survival at 12 months.

  • Zacks Small Cap Research

    SNGX: Innate Defense Regulators Offer New Approach to Treating Infections

    Soligenix, Inc. (SNGX) recently published a review of the potential clinical applications for innate defense regulators (IDRs), including the company’s lead IDR asset SGX942. IDRs modulate the innate immune response, which is composed of both physical barriers (e.g., skin, mucosal surfaces, etc.) as well as specialized myeloid and lymphoid sensor and effector cells (Gasteiger et al., 2017). IDRs exert their effects through binding of p62 (sequestosome-1), which is involved in a number of different innate immune signaling networks (Yu et al., 2009).

  • Benzinga

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...

  • Zacks Small Cap Research

    SNGX: Two Phase 3 Data Readouts Over Next 12-15 Months…

    Revenues were comprised of non-dilutive government grants and contracts in support of RiVax®, SGX301, and SGX942 as well as a subaward from the Ebola collaboration with the University of Hawaii. The increase was mainly due to increased costs associated with the ongoing Phase 3 clinical trials. As of September 30, 2018, Soligenix had cash and cash equivalents of $11.7 million, due in part to a registered direct offering in July 2018 that raised net proceeds of $8.4 million.

  • Zacks Small Cap Research

    SNGX: Transferring Coverage; Positive Feedback from Interim Analysis gives SGX301 Phase 3 Trial 90% probability of success…

    On October 15, 2018, Soligenix, Inc. (SNGX) announced a positive recommendation from the independent Data Monitoring Committee (DMC), which conducted an unblinded analysis of the company’s ongoing Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial. The trial is testing the company’s lead product, SGX301, as a treatment for cutaneous T cell lymphoma (CTCL). The DMC recommended that the company enroll an additional 40 subjects into the trial to maintain 90% statistical power for the primary endpoint.

  • Zacks Small Cap Research

    SNGX: Q&A with Soligenix Chief Medical Officer Dr. Richard Straube Regarding the Interim Analysis for the Phase 3 Trial of SGX301

    To clear up any confusion regarding the DMC’s recommendation and what it means for the study we spoke with Dr. Richard Straube, Soligenix’s Chief Medical Officer, and asked him a few questions regarding the outcome of the interim analysis. David Bautz: Some investors may be surprised by the required addition of 40 patients to the study. Dr. Straube: First, we want to make it clear that nothing is wrong with the study and we weren’t far off with our estimated enrollment of approximately 120 patients.

  • Benzinga

    The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs

    As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...

  • Zacks Small Cap Research

    SNGX: What Can We Expect from the Upcoming Interim Analysis of Phase III SGX301 for CTCL?

    Soligenix (SNGX) is a late-stage biopharmaceutical company with two Phase III candidates. While we are waiting for the interim analysis of SGX301 in the coming month, we recently interviewed Dr. Richard C. Straube, Sr. VP & Chief Medical Officer of Soligenix (SNGX) with respect to the prospect of this late stage candidate. Following are the summary of what we get from Dr. Richard Straube.